Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01627-8
Abstract: Recently the phase 3 BEACON trial showed that the combination of encorafenib, cetuximab, and binimetinib versus cetuximab and irinotecan/FOLFIRI improved overall survival in pre-treated patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutation. However,… read more here.
Keywords: braf v600e; cetuximab; cost effectiveness; cost ... See more keywords
BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer letters"
DOI: 10.1016/j.canlet.2020.11.036
Abstract: BRAFV600- and MEK1/2-targeting therapies rarely produce durable response in melanoma patients. We investigated five BRAFV600E melanoma cell lines derived from drug-naïve tumor specimens to assess cell death response to encorafenib (Braftovi), a recently FDA-approved BRAFV600… read more here.
Keywords: brafv600e melanoma; apoptosis; bcl; cell ... See more keywords
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.07.016
Abstract: BACKGROUND Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or photosensitivity depending on… read more here.
Keywords: adverse events; encorafenib; columbus study; encorafenib binimetinib ... See more keywords
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.02659
Abstract: PURPOSE Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600–mutant melanoma. Here, we… read more here.
Keywords: year; braf v600; encorafenib; v600 mutant ... See more keywords